Skip to main content

Atossa Increases Anticipated Proceeds from Pending IPO

NEW YORK (GenomeWeb News) – Atossa Genetics, which refiled for an initial public offering earlier this year after withdrawing from an earlier attempt, today revised the estimate on how much the offering may garner.

In a Form S-1/A, the Seattle-based firm said that at the $5 midpoint of the expected price range for its shares, between $4 and $6, the IPO would bring in $5.4 million, or $6.2 million if underwriters exercise the overallotment option. Dawson James Securities is listed in its IPO filing as the underwriter.

When Atossa refiled its IPO in February, it said shares would fetch between $5 and $7, raising about $4.9 million, or $5.7 million if underwriters exercised their overallotment option.

The firm originally planned to offer 1 million shares. In August it increased the number of shares planned in the offering to 1.2 million shares, but lowered the price range to between $4 and $6. Last month it increased again the number of shares in the offering to 1.3 million shares.

The company also has revised the amount it needs to raise for approval to list on the Nasdaq Capital Market to at least $4 million in gross proceeds. Atossa previously said that it needed to raise at least $6 million, then increased the figure to $6.25 million.

Atossa plans to list its shares under ticker symbol "ATOS".

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.